Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q1 2020 · 10-Q
Revenue$24.40M$24.40M+2.3% vs Q1 2019 Net Income-$78.35M-$78.35MN/M vs Q1 2019 EPS Diluted-$0.89-$0.89N/M vs Q1 2019 Operating Income-$81,074,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Free Cash Flowderived-$59,945,000N/M Margins · derivedOperating margin-332.3%−127.6 pt vs Q1 2019
Net margin-321.1%−130.8 pt vs Q1 2019
ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end